Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.

about

Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma.Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.

P2860

Q38932565-A6B05A34-D064-4EA2-B73B-C24A1DFB1365 Q41033340-EDE60563-86B2-4734-B81D-BF3F4131AFC9

P2860

Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.

Item

http://www.wikidata.org/entity/Q39281507

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Targeting EGFR-positive cancer ...... in vitro and in vivo studies.

@en

Targeting EGFR-positive cancer ...... in vitro and in vivo studies.

@nl

type

Item

label

Targeting EGFR-positive cancer ...... in vitro and in vivo studies.

@en

Targeting EGFR-positive cancer ...... in vitro and in vivo studies.

@nl

prefLabel

Targeting EGFR-positive cancer ...... in vitro and in vivo studies.

@en

Targeting EGFR-positive cancer ...... in vitro and in vivo studies.

@nl

P1476

Targeting EGFR-positive cancer ...... in vitro and in vivo studies.

@en

P2093

Akiva Vexler

http://www.w3.org/2001/XMLSchema#string

Itai Benhar

http://www.w3.org/2001/XMLSchema#string

Itay Barnea

http://www.w3.org/2001/XMLSchema#string

Rahamim Ben-Yosef

http://www.w3.org/2001/XMLSchema#string

Victoria Karaush

http://www.w3.org/2001/XMLSchema#string

P2860

Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A

Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

Arming antibodies: prospects and challenges for immunoconjugates.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Antibodies and their fragments as anti-cancer agents.

Targeted therapy of cancer: new prospects for antibodies and immunoconjugates.

Technology insight: cytotoxic drug immunoconjugates for cancer therapy.

P304

1171-1177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HED.23093

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22965815

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab

Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.

about

P2860

P2860

Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921